ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment

期刊论文
发表日期：

2024年11月29日

查看全文

Marine Bruciamacchie,
Véronique Garambois,
Nadia Vie,
Thomas Bessede,
Henri-Alexandre Michaud,
Laure-Agnès Chepeaux,
Laurent Gros,
Nathalie Bonnefoy,
Mathilde Robin,
Dorian Brager,
Kevin Bigot,
Alexandre Evrard,
Philippe Pourquier,
Jacques Colinge,
Muriel Mathonnet,
Ismahane Belhabib,
Christine Jean,
Corinne Bousquet,
Pierre-Emmanuel Colombo,
Marta Jarlier,
Diégo Tosi,
Céline Gongora,
Christel Larbouret

摘要

Background

In pancreatic ductal adenocarcinoma (PDAC), the dense stroma rich in cancer-associated fibroblasts (CAFs) and the immunosuppressive microenvironment confer resistance to treatments. To overcome such resistance, we tested the combination of FOLFIRINOX (DNA damage-inducing chemotherapy drugs) with VE-822 (an ataxia-telangiectasia and RAD3-related inhibitor that targets DNA damage repair).

Methods

PDAC spheroid models and organoids were used to assess the combination effects. Tumour growth and the immune and fibrotic microenvironment were evaluated by immunohistochemistry, single-cell analysis and spatial proteomics in patient-derived xenograft (PDX) and orthotopic immunocompetent KPC mouse models.

Results

The FOLFIRINOX and VE-822 combination had a strong synergistic effect in several PDAC cell lines, whatever their BRCA1, BRCA2 and ATM mutation status and resistance to standard chemotherapy agents. This was associated with high DNA damage and inhibition of DNA repair signalling pathways, leading to increased apoptosis. In immunocompetent and PDX mouse models of PDAC, the combination inhibited tumour growth more effectively than FOLFIRINOX alone. This was associated with tumour microenvironment remodelling, particularly decreased proportion of fibroblast activated protein-positive CAFs and increased anti-tumorigenic immune cell infiltration and interaction.

Conclusion

The FOLFIRINOX and VE-822 combination is a promising strategy to improve FOLFIRINOX efficacy and overcome drug resistance in PDAC.